全文获取类型
收费全文 | 101篇 |
免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 7篇 |
口腔科学 | 5篇 |
临床医学 | 9篇 |
内科学 | 23篇 |
皮肤病学 | 1篇 |
神经病学 | 1篇 |
特种医学 | 4篇 |
外科学 | 20篇 |
一般理论 | 1篇 |
预防医学 | 3篇 |
药学 | 9篇 |
肿瘤学 | 13篇 |
出版年
2014年 | 1篇 |
2013年 | 3篇 |
2012年 | 6篇 |
2011年 | 3篇 |
2010年 | 6篇 |
2009年 | 5篇 |
2008年 | 1篇 |
2007年 | 4篇 |
2006年 | 11篇 |
2005年 | 14篇 |
2004年 | 12篇 |
2003年 | 10篇 |
2002年 | 16篇 |
1999年 | 2篇 |
1998年 | 3篇 |
1994年 | 1篇 |
1992年 | 2篇 |
1991年 | 3篇 |
排序方式: 共有103条查询结果,搜索用时 15 毫秒
1.
Evagelos N Liberopoulos Eleni Papavasiliou George A Miltiadous Marios Cariolou Kostas C Siamopoulos Alexandros D Tselepis Moses S Elisaf 《Peritoneal dialysis international》2004,24(6):580-589
OBJECTIVE: The more atherogenic lipid profile seen in peritoneal dialysis (PD) patients cannot fully explain the increased incidence of atherosclerosis in this population. Oxidative modification of low-density lipoproteins (LDL) is considered to play a central role in the atherogenic process, whereas high-density lipoprotein (HDL) protects LDL from oxidation. On the other hand, it has been suggested that the LDL and HDL of PD patients are more resistant to oxidation than those of control subjects, while PD-HDL equally protects LDL from oxidation compared to control-HDL. Two HDL-associated enzymes have been shown to protect both LDL and HDL from oxidation: paraoxonase (PON1) and HDL-associated platelet-activating factor acetylhydrolase (HDL-PAF-AH). Furthermore, low PON1 activity and high total plasma PAF-AH concentration, which represents mainly the LDL-associated enzyme, have been shown to be independent risk factors for coronary artery events in the general population. However, there are limited data regarding possible alterations of these enzymes in PD patients. The aim of our study was to examine the possible alterations of PON1 and PAF-AH activities in patients undergoing PD. DESIGN: A cross-sectional study. SETTING: A university medical center. PARTICIPANTS: 56 PD patients of Caucasian origin and 86 matched controls were studied. MEASUREMENTS: In all subjects, serum PON1 activity toward paraoxon (paraoxonase) and phenylacetate (arylesterase), as well as total serum and HDL-PAF-AH activities were measured; PON1 genetic polymorphisms known to influence PON1 activity (Q192R and M55L) were determined. RESULTS: The PD patients exhibited significantly increased serum PON1 (paraoxonase) and PON1 (arylesterase) activities compared to controls, regardless of the PON1 polymorphisms or the levels of HDL cholesterol. Additionally, PD patients had significantly elevated activities of total serum PAF-AH and HDL-PAF-AH, independently of the levels of LDL or HDL cholesterol. The ratio of HDL-PAF-AH/ total PAF-AH, which has recently been suggested to be a potential marker of atherogenicity, was decreased in these patients compared to controls. Moreover, no difference in the prevalence of PON1 polymorphisms between PD patients and controls was found. CONCLUSION: The elevated activities of PON1 and HDL-PAF-AH could explain the increased resistance of PD-HDL to oxidation; the higher activity of total PAF-AH and the decreased HDL-PAF-AH/ total PAF-AH ratio could contribute to the increased incidence of atherosclerosis in these patients. 相似文献
2.
Evagelos Liberopoulos Fotini Apostolou Moses Elisaf 《Nephrology, dialysis, transplantation》2004,19(5):1328-9; author reply 1329-30
3.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. 总被引:23,自引:0,他引:23
Aristotle Bamias Efstathios Kastritis Christina Bamia Lia A Moulopoulos Ioannis Melakopoulos George Bozas Vassiliki Koutsoukou Dimitra Gika Athanasios Anagnostopoulos Christos Papadimitriou Evagelos Terpos Meletios A Dimopoulos 《Journal of clinical oncology》2005,23(34):8580-8587
PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases. PATIENTS AND METHODS: ONJ was assessed prospectively since July 2003. The first bisphosphonate treatment among patients with ONJ was administered in 1997. Two hundred fifty-two patients who received bisphosphonates since January 1997 were included in this analysis. RESULTS: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289). The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months. The cumulative hazard was significantly higher with zoledronic acid compared with pamidronate alone or pamidronate and zoledronic acid sequentially (P < .001). All but two patients with ONJ had a history of dental procedures within the last year or use of dentures. CONCLUSION: The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor. 相似文献
4.
5.
6.
7.
8.
9.
Liberopoulos E Alexandridis G Elisaf M 《Annals of clinical and laboratory science》2002,32(4):419-421
Reported herein for the first time in the literature is the case of a 41-yr-old woman who developed a tumor lysis-like syndrome, consisting of hyperkalemia, hyperphosphatemia, hyperuricemia, and acute renal insufficiency, soon after the initiation of chemotherapy for severe visceral leishmaniasis with liposomal amphotericin B. Allopurinol therapy, together with iv fluid administration and urine alkalization, resulted in full recovery of the metabolic abnormalities. Awareness of this condition can lead to prophylactic treatment as well as the early recognition and management of susceptible patients. 相似文献
10.
Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review 总被引:1,自引:0,他引:1
Multicentric Castleman's disease is increasingly recognized as an aggressive illness with a rapidly fatal outcome in human immunodeficiency virus (HIV)-infected patients. In the absence of optimal therapy, various therapeutic interventions have been tested with disappointing results; only five reports with a successful outcome have been described. Presented herein is a 66-year-old HIV-infected man with multicentric Castleman's disease. Early administration of cyclophosphamide, doxorubicin, vincristine and prednisone resulted in prolonged clinical recovery. The relevant literature is also reviewed. 相似文献